Corpus Intelligence IC Memo — NORTHERN COLORADO LONG TERM ACUTE HO 2026-04-26 22:10 UTC
IC Memo — NORTHERN COLORADO LONG TERM ACUTE HO
Investment Committee Memorandum | CO | 20 beds | Grade C | EBITDA uplift $923K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NORTHERN COLORADO LONG TERM ACUTE HO

CCN 062017 | LARIMER, CO | 20 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NORTHERN COLORADO LONG TERM ACUTE HO is a 20-bed safety-net/medicaid heavy in LARIMER, CO with $12.5M in net patient revenue and a 17.5% operating margin. The hospital serves a payer mix of 22.6% Medicare, 38.0% Medicaid, and 39.4% commercial.

Thesis: Turnaround. Our ML models identify $923K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 17.5% to 24.8% (+738bps).

Net Revenue HCRIS$12.5M
Current EBITDA COMPUTED$2.2M
Operating Margin COMPUTED17.5%
Occupancy HCRIS86.5%
Revenue / Bed COMPUTED$625K
Net-to-Gross HCRIS56.8%
Distress Probability ML51.5%

2. Market Context & Competitive Position

108
CO Hospitals
-3.6%
State Median Margin
46
Comparable Hospitals

CO has 108 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of 17.5% places it above the state median. Among 46 size-comparable peers (10-40 beds), the median margin is -5.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 46 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NORTHERN COLORADO LONG TERM AC (Target)CO20$12.5M17.5%
VALLEY VIEW HOSPITALCO31$285.3M-3.1%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
ASPEN VALLEY HOSPITAL DISTRICTCO25$130.1M0.4%
CENTURA ST. ANTHONY SUMMIT HOSCO34$121.5M28.8%
HEART OF THE ROCKIES REG MED CCO25$117.5M5.4%
YAMPA VALLEY MEDICAL CENTERCO34$116.6M-6.9%
GRAND RIVER HOSPITAL DISTRICTCO25$85.2M-30.8%
CENTURA ST. THOMAS MORE HOSPITCO25$83.7M18.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $923K (738bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$262K+210bp18mo
Cost to Collect4.5%2.5%$250K+200bp12mo
Denial Rate Reduction12.0%6.5%$249K+199bp12mo
A/R Days Reduction5200.0%3800.0%$152K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$262K
Cost to Collect
$250K
Denial Rate Reduction
$249K
A/R Days Reduction
$152K
Clean Claim Rate
$10K
Total EBITDA Uplift$923K
Current EBITDA$2.2M
+ RCM Uplift+$923K
Pro Forma EBITDA$3.1M
Current Margin17.5%
Pro Forma Margin24.8%
WC Released (1x)$479K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.4M$23.6M7.04x47.7%
Base (11x exit)10.0x11.0x$3.4M$27.1M8.07x51.8%
Bull Case9.0x11.0x$3.0M$31.2M10.33x59.5%
Bull (12x exit)9.0x12.0x$3.0M$34.9M11.57x63.2%
Bear Case11.0x10.0x$3.7M$17.9M4.85x37.1%
Bear (11x exit)11.0x11.0x$3.7M$20.9M5.66x41.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (38.0%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 51.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 46 hospitals with 10-40 beds
  • Same-state prioritization (n=47)
  • Comp margins: P25=-15.3% / P50=-5.8% / P75=2.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.